SecBot SecBot
SECBOTREPLAY Home › Report › OCGN

OCGN · Ocugen dosed the first patient in the global Phase 3 ArMaDa3 trial of…

Ocugen · PRESS-RELEASE filed Sep 1, 2026 at 07:02 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Sep 1, 2026 at 07:02 ET

Ocugen dosed the first patient in the global Phase 3 ArMaDa3 trial of OCU410 for geographic atrophy (GA) and highlighted recent FDA RMAT designation. The Phase 3 design is aligned with FDA, and a BLA filing is anticipated in 2028. The RMAT designation and Phase 2 data showing 31% lesion growth reduction de-risk the program, but the long timeline to BLA (2028) and the small Phase 3 enrollment (237 subjects) limit near-term trading impact.

  • First patient dosed in global Phase 3 registrational trial (ArMaDa3) of OCU410 for geographic atrophy (GA) secondary to dry AMD.
  • FDA granted RMAT designation for OCU410 on July 29, 2026, providing eligibility for accelerated approval and priority review.
  • Phase 3 design fully aligned with FDA; BLA filing anticipated in 2028.
  • Phase 2 data showed 31% reduction in GA lesion growth at 12 months with the optimal dose vs. control (p<0.05), and no drug-related serious adverse events.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access